Top Biotech Companies in Sydney (26)
Novotech is a global full‑service clinical research organization (CRO) and scientific advisory partner that provides clinical trial execution, regulatory, laboratory and consulting services to biotech and small- to mid‑sized pharmaceutical companies. Operating across the Asia‑Pacific region and beyond with multiple offices and strategic site partnerships, Novotech helps sponsors accelerate development and access diverse patient populations for global drug development.
At Eucalyptus, we run a trusted group of digital healthcare clinics on our telehealth platform including Pilot (men’s health), Kin (fertility), Software (dermatology) and Juniper (weight loss and menopause). Our mission is to bring high-touch, high-quality healthcare to patients around the world by empowering practitioners with technology. Since 2019, we’ve facilitated over one million consultations across Australia, the UK and...
Defining and optimising TBI diagnosis and prognosis to maximise patient outcomes.To increase the understanding of brain related injury with particular emphasis on concussion (mTBI) through ongoing research and education, and to ultimately validate a biomarker(s) that will be used in combination with dedicated point of care (POC) device as a definitive diagnostic/prognostic tool. A group of dedicated professionals working in collaboration...
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Smith & Nephew's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show mid-single-digit underlying growth through 2024–2025, with management reiterating guidance for continued growth in 2026. Early 2026 updates indicate broad-based contributions across units despite some subsegment variability.
Profitability: Trading profit and margins improved, supported by execution of the 12‑Point Plan and the transition to the RISE strategy. Management is guiding to further profit growth alongside higher returns.
Healthy Cash Flow: Free cash flow strengthened in 2025 with guidance for robust generation in 2026. Share repurchases completed and newly announced buybacks signal confidence and disciplined capital allocation.
Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed...
EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy....
2San is a global diagnostics company that provides innovative home-testing and diagnostic solutions to empower individuals to take control of their health. Focusing on areas such as infection, drugs of abuse, and family planning, the company aims to make high-quality healthcare accessible and affordable for everyone through its goal of 'self-testing for all.'
Building with biology. Hydrogen and Renewable Energy, On-site and On-Demand
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Standard BioTools's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The sale of the SomaLogic business to Illumina provided substantial cash proceeds, leaving the company with a strong cash and investment position to pursue M&A. Management cites enhanced balance sheet flexibility to support an inorganic growth strategy.
Cost & Operational Efficiency: Management has fully operationalized significant annualized cost savings and reduced operating expenses. Targets for positive adjusted EBITDA and adjusted cash flow by the end of 2026 indicate continued focus on efficiency.
Strong Market Position & Advantage: The company is widely recognized as a leader in mass cytometry and imaging mass cytometry through its CyTOF and Hyperion platforms. Ongoing platform updates and ecosystem signals point to durable leadership within these niches.
At the heart of our mission lies the fusion of nature and science, driven by the desire to offer the world nature-identical proteins that are as familiar as they are sustainable. What sets us apart? No animals are involved, no additional land is required, and we are firmly committed to conserving water. How We Achieve It: Through the remarkable field...
Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point. We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.
Ingram Micro helps businesses Realize the Promise of Technology™. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and...
Ingram Micro's Top Stability & Growth Strengths
Strong Revenue Growth: Company updates show net sales grew in FY2025 and continued to rise year over year into early 2026, with multiple consecutive growth quarters during 2025. Feedback suggests momentum was broad‑based across regions and core lines such as Cloud, notebooks/endpoint, and Advanced Solutions.
Strong Market Position & Advantage: Industry coverage consistently places the company among the top two global IT distributors by revenue, reinforced by deep vendor relationships and extensive geographic reach. Feedback suggests this leadership position supports ecosystem influence and partner access across hardware, software, and cloud.
Innovation-Driven Growth: Management highlights the Xvantage digital platform and cloud marketplace as drivers improving partner experience and sell‑through. Evidence in the updates links platform investment to gains in Cloud and services and to the return to year‑over‑year growth exiting 2024 and through 2025.
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring,...
.png)
Ancestry is the global leader in family history and consumer genomics. Every day, around the world, we help curious people like you embark on journeys of personal discovery to enrich lives. With our unparalleled collection of more than 40 billion records from more than 80 countries and 23+ million people in our growing DNA network, Ancestry helps customers discover their family...
Ancestry's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company communications and industry coverage consistently depict Ancestry as the category leader, citing tens of billions of records, millions of subscribers, and the world’s largest consumer DNA network. Blackstone’s 2020 acquisition and a weakened rival landscape (e.g., 23andMe’s 2025 bankruptcy) reinforce its durable leadership.
Product Line Growth: Content and features expanded with 243 new historical collections in 2025, the largest-ever ethnicity update, and the iMemories acquisition adding media digitization. AI-enabled processing accelerates turning archives into searchable data, signaling ongoing product and data-scale growth.
Market Expansion: The company launched services in Italy and the Netherlands in 2025 and reported strong subscriber scale alongside rising community uploads. A multiyear partnership with the U.S. National Archives supports continued content expansion that benefits multiple markets.
KCR is a clinical development solutions provider creating value for emerging biotechnology organizations. Founded in 1997, our expert teams support clients with full-service clinical development capabilities. As part of the ICON organization, KCR serves clients globally with key operations hubs in Boston, US, Berlin, Germany, and Warsaw, Poland. KCR’s bespoke approach to service delivery for emerging Biotech companies combined with the...
We exist to help make medical research breakthroughs happen by expediting and enabling a better clinical trial process - for everybody. Our suite of purpose-built and owned Evrima products and services are born of the clinical trial sector and are inherently solutions-focused. We efficiently and accurately connect a diverse range of trial participants, researchers and clinicians, delivering an optimum clinical...
Levur produces natural-identical oils, without the environmental impact. Our vision is a future where reliance on unsustainable plant and animal oils like Palm Oil or Tallow is drastically reduced, mitigating environmental impacts. From our base in Australia, we are collaborating with large consumer goods manufacturers to make this a reality at scale and ensure ethical alternatives are available to consumers...
